Toll-like receptor 2 mediated dendritic cell activation-key target for lipopeptide vaccines design

Dendritic Cells: Types, Life Cycles and Biological Functions

Volumn , Issue , 2010, Pages 63-80

  Zaman, Mehfuz ^a   Skwarczynski, Mariusz ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017047360     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (127)

1. Perrie, Y; Mohammed, AR; Kirby, DJ; McNeil, SE; Bramwell, VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm, 2008, Dec 8, 364(2), 272-80.
2. Ehreth, J. The global value of vaccination. Vaccine, 2003, Jan 30, 21(7-8), 596-600.
3. Kaufmann, SH. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol, 2007 Jul, 5(7), 491-504.
4. Ishii, KJ; Akira, S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol, 2007, Jul, 27(4), 363-71.
5. Brown, LE; Jackson, DC. Lipid-based self-adjuvanting vaccines. Curr Drug Deliv, 2005, Oct, 2(4), 383-93.
6. Asai, Y; Makimura, Y; Ogawa, T. Toll-like receptor 2-mediated dendritic cell activation by a Porphyromonas gingivalis synthetic lipopeptide. J Med Microbiol, 2007, Apr, 56(Pt 4), 459-65.
7. Mellman, I; Steinman, RM. Dendritic cells: specialized and regulated antigen processing machines. Cell, 2001, Aug 10, 106(3), 255-8.
8. Sun, Y; Santra, S; Schmitz, JE; Roederer, M; Letvin, NL. Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J Virol, 2008 Sep, 82(17), 8812-9.
9. Van Duin, D; Medzhitov, R; Shaw, AC. Triggering TLR signaling in vaccination. Trends Immunol, 2006, Jan, 27(1), 49-55.
10. Akira, S; Uematsu, S; Takeuchi, O. Pathogen recognition and innate immunity. Cell, 2006, Feb 24, 124(4), 783-801.
11. Pasare, C; Medzhitov, R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect, 2004, Dec, 6(15), 1382-7.
12. Uematsu, S; Akira, S. Toll-like receptors and innate immunity. J Mol Med, 2006, Sep, 84(9), 712-25.
13. Kawai, T; Akira, S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol, 2005, Aug, 17(4), 338-44.
14. Banchereau, J; Steinman, RM. Dendritic cells and the control of immunity. Nature, 1998, Mar 19, 392(6673), 245-52.
15. Steinman, RM; Hemmi, H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol, 2006, 311, 17-58.
16. Guermonprez, P; Valladeau, J; Zitvogel, L; Thery, C; Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol, 2002, 20, 621-67.
17. Batista, FD; Neuberger, MS. B cells extract and present immobilized antigen: implications for affinity discrimination. EMBO J, 2000, Feb 15, 19(4), 513-20.
18. Trombetta, ES; Mellman, I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol, 2005, 23, 975-1028.
19. Coffman, RL. Mechanisms of helper T-cell regulation of B-cell activity. Ann N Y Acad Sci, 1993, Jun 21, 681, 25-8.
20. Coffman, RL; Seymour, BW; Lebman, DA; Hiraki, DD; Christiansen, JA; Shrader, B; et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev, 1988, Feb, 102, 5-28.
21. Coffman, RL; Mosmann, TR. Isotype regulation by helper T cells and lymphokines. Monogr Allergy, 1988, 24, 96-103.
22. Steinman, RM. Linking innate to adaptive immunity through dendritic cells. Novartis Found Symp, 2006, 279, 101-9; discussion 9-13, 216-9.
23. Guery, JC; Adorini, L. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol, 1995, Jan 15, 154(2), 536-44.
24. Clark, R; Kupper, T. Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol, 2005, Oct, 125(4), 629-37.
25. Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev, 2004 Jun, 199, 227-50.
26. Woodland, DL. Vaccination strategies. Viral Immunol, 2008, Mar, 21(1), 1-2.
27. Steinman, RM; Pope, M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest, 2002, Jun, 109(12), 1519-26.
28. Ahlers, JD; Belyakov, IM. Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines. Trends Mol Med, 2009, Jun, 15(6), 263-74.
29. Shortman, K; Lahoud, MH; Caminschi, I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med, 2009, Feb 28, 41(2), 6.
30. Honda, K; Sakaguchi, S; Nakajima, C; Watanabe, A; Yanai, H; Matsumoto, M; et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci, U S A 2003, Sep 16, 100(19), 10872-7.
31. Bauer, M; Redecke, V; Ellwart, JW; Scherer, B; Kremer, JP; Wagner, H; et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol, 2001 Apr 15, 166(8), 5000-7.
32. Sancho, D; Joffre, OP; Keller, AM; Rogers, NC; Martinez, D; Hernanz-Falcon, P; et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature, 2009, Apr 16, 458(7240), 899-903.
33. Bruna-Romero, O; Rodriguez, A. Dendritic cells can initiate protective immune responses against malaria. Infect Immun, 2001, Aug, 69(8), 5173-6.
34. Krogsgaard, M; Davis, MM. How T cells ‘see’ antigen. Nat Immunol, 2005, Mar, 6(3), 239-45.
35. Cole, DK; Dunn, SM; Sami, M; Boulter, JM; Jakobsen, BK; Sewell, AK. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol, 2008, May, 45(9), 2700-9.
36. Hwang, I; Huang, JF; Kishimoto, H; Brunmark, A; Peterson, PA; Jackson, MR; et al. T cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived from antigen-presenting cells. J Exp Med, 2000, Apr 3, 191(7), 1137-48.
37. Wang, JH; Reinherz, EL. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol Immunol, 2002, May, 38(14), 1039-49.
38. Appleman, LJ; Boussiotis, VA. T cell anergy and costimulation. Immunol Rev, 2003, Apr, 192, 161-80.
39. Watts, TH; Bertram, EM; Bukczynski, J; Wen, T. T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines. Can J Infect Dis, 2003, Jul, 14(4), 221-9.
40. Ward, RC; Kaufman, HL. Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol, 2007, May-Aug, 26(3-4), 161-96.
41. Sharpe, AH; Freeman, GJ. The B7-CD28 superfamily. Nat Rev Immunol, 2002, Feb, 2(2), 116-26.
42. Carreno, BM; Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol, 2002, 20, 29-53.
43. Bour-Jordan, H; Blueston, JA. CD28 function: a balance of costimulatory and regulatory signals. J Clin Immunol, 2002, Jan, 22(1), 1-7.
44. Greenfield, EA; Nguyen, KA; Kuchroo, VK. CD28/B7 costimulation: a review. Crit Rev Immunol, 1998, 18(5), 389-418.
45. Behar, SM; Porcelli, SA; Beckman, EM; Brenner, MB. A pathway of costimulation that prevents anergy in CD28-T cells: B7-independent costimulation of CD1-restricted T cells. J Exp Med, 1995, Dec 1, 182(6), 2007-18.
46. Schwartz, RH. T cell anergy. Annu Rev Immunol, 2003, 21, 305-34.
47. Kapsenberg, ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol, 2003, Dec, 3(12), 984-93.
48. Langenkamp, A; Messi, M; Lanzavecchia, A; Sallusto, F. Kinetics of dendritic cell activation: impact on priming of TH1; TH2 and nonpolarized T cells. Nat Immunol, 2000, Oct, 1(4), 311-6.
49. Feili-Hariri, M; Falkner, DH; Morel, PA. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol, 2005, Sep, 78(3), 656-64.
50. Lewandowski, D; Marquis, M; Aumont, F; Lussier-Morin, AC; Raymond, M; Senechal, S; et al. Altered CD4+ T cell phenotype and function determine the susceptibility to mucosal candidiasis in transgenic mice expressing HIV-1. J Immunol, 2006, Jul 1, 177(1), 479-91.
51. Mohammadi, M; Nedrud, J; Redline, R; Lycke, N; Czinn, SJ. Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology, 1997, Dec, 113(6), 1848-57.
52. Lopez-Diaz de Cerio, A; Lasarte, JJ; Casares, N; Sarobe, P; Ruiz, M; Prieto, J; et al. Engineering Th determinants for efficient priming of humoral and cytotoxic T cell responses. Int Immunol, 2003, Jun, 15(6), 691-9.
53. Levings, MK; Sangregorio, R; Roncarolo, MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med, 2001, Jun 4, 193(11), 1295-302.
54. Mills, KH. Regulatory, T. cells: friend or foe in immunity to infection? Nat Rev Immunol, 2004, Nov, 4(11), 841-55.
55. Nimmerjahn, F; Ravetch, JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science, 2005, Dec 2, 310(5753), 1510-2.
56. Yuan, RR; Spira, G; Oh, J; Paizi, M; Casadevall, A; Scharff, MD. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect Immun, 1998, Mar, 66(3), 1057-62.
57. Neyestani, TR; Woodward, B. Blood concentrations of Th2-type immunoglobulins are selectively increased in weanling mice subjected to acute malnutrition. Exp Biol Med (Maywood), 2005, Feb, 230(2), 128-34.
58. Mora, JR; Cheng, G; Picarella, D; Briskin, M; Buchanan, N; von Andrian, UH. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med, 2005, Jan 17, 201(2), 303-16.
59. Beltman, JB; Maree, AF; de Boer, RJ. Spatial modelling of brief and long interactions between T cells and dendritic cells. Immunol Cell Biol, 2007, Jun, 85(4), 306-14.
60. Seya, T; Matsumoto, M; Tsuji, S; Begum, NA; Azuma, I; Toyoshima, K. Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. Microbes Infect, 2002, Jul, 4(9), 955-61.
61. De Smedt, T; Pajak, B; Muraille, E; Lespagnard, L; Heinen, E; De Baetselier, P; et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med, 1996, Oct 1, 184(4), 1413-24.
62. Cella, M; Salio, M; Sakakibara, Y; Langen, H; Julkunen, I; Lanzavecchia, A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med, 1999, Mar 1, 189(5), 821-9.
63. Muzio, M; Bosisio, D; Polentarutti, N; D’Amico, G; Stoppacciaro, A; Mancinelli, R; et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol, 2000, Jun 1, 164(11), 5998-6004.
64. Venugopal, PG; Nutman, TB; Semnani, RT. Activation and regulation of toll-like receptors (TLRs) by helminth parasites. Immunol Res, 2009, 43(1-3), 252-63.
65. Bell, JK; Mullen, GE, Leifer, CA; Mazzoni, A; Davies, DR; Segal, DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol, 2003, Oct, 24(10), 528-33.
66. Akira, S; Sato, S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis, 2003, 35(9), 555-62.
67. Zhang, G; Ghosh, S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest, 2001, Jan, 107(1), 13-9.
68. Duramad, O; Fearon, KL; Chang, B; Chan, JH; Gregorio, J; Coffman, RL; Barrat, FJ. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol, 2005, 174(9), 5193-200.
69. Rharbaoui, F; Drabner, B; Borsutzky, S; Winckler, U; Morr, M; Ensoli, B; Muhlradt, PF; Guzman, CA. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol, 2002, 32(10), 2857-65.
70. Caramalho, I; Lopes-Carvalho, T; Ostler, D; Zelenay, S; Haury, M; Demengeot, J. Regulatory, T. cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med, 2003, 197(4), 403-11.
71. Guy, B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol, 2007, 5(7), 505-17.
72. Herlands, RA; Christensen, SR; Sweet, RA; Hershberg, U; Shlomchik, MJ. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity, 2008, 29(2), 249-60.
73. Netea, MG; Van der Meer, JW; Sutmuller, RP; Adema, GJ; Kullberg, BJ. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother, 2005, 49(10), 3991-6.
74. Corthay, A. A three-cell model for activation of naive T helper cells. Scand J Immunol, 2006, 64(2), 93-6.
75. Blander, JM; Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature, 2006, 440(7085), 808-12.
76. Blander, JM. Phagocytosis and antigen presentation: a partnership initiated by Toll-like receptors. Ann Rheum Dis, 2008, 67, Suppl 3:iii 44-9.
77. Schnare, M; Barton, GM; Holt, AC; Takeda, K; Akira, S; Medzhitov, R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol, 2001, Oct, 2(10), 947-50.
78. Hayashi, S; Wu, HC. Lipoproteins in bacteria. J Bioenerg Biomembr, 1990, 22(3), 451-71.
79. Into, T; Dohkan, J; Inomata, M; Nakashima, M; Shibata, K; Matsushita, K. Synthesis and characterization of a dipalmitoylated lipopeptide derived from paralogous lipoproteins of Mycoplasma pneumoniae. Infect Immun, 2007, 75(5), 2253-9.
80. Zuo, LL; Wu, YM; You, XX. Mycoplasma lipoproteins and Toll-like receptors. J Zhejiang Univ Sci B, 2009, 10(1), 67-76.
81. Akira, S; Uematsu, S; Takeuchi, O. Pathogen recognition and innate immunity. Cell, 2006, 124(4), 783-801.
82. Farhat, K; Riekenberg, S; Heine, H; et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol, 2008, 83(3), 692-701.
83. Chua, BY; Zeng, W; Jackson, DC. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Methods Mol Biol, 2008, 494, 247-61.
84. Chua, BY; Eriksson, EM; Brown, LE; Zeng, W; Gowans, EJ; Torresi, J; Jackson, DC. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine, 2008, 26(37), 4866-75.
85. Durier, C; Launay, O; Meiffredy, V; et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS, 2006, 20(7), 1039-49.
86. Gahery, H; Choppin, J; Bourgault, I; Fischer, E; Maillere, B; Guillet, JG. HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach. Therapie, 2005, 60(3), 243-8.
87. Ghielmetti, M; Reschner, A; Zwicker, M; Padovan, E. Synthetic bacterial lipopeptide analogs: structural requirements for adjuvanticity. Immunobiology, 2005, 210(2-4), 211-5.
88. Mittenbuhler, K; v d Esche, U; Heinevetter, L; Bessler, WG; Huber, M. Lipopeptides: adjuvanticity in conventional and genetic immunization. FEMS Immunol Med Microbiol, 2003, 37(2-3), 193-200.
89. Seya, T; Matsumoto, M. A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2. Int J Biochem Cell Biol, 2002, 34(8), 901-6.
90. Zeng, W; Ghosh, S; Lau, YF; Brown, LE; Jackson, DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol, 2002, 169(9), 4905-12.
91. Reschner, A; Moretta, A; Landmann, R; Heberer, M; Spagnoli, GC; Padovan, E. The ester-bonded palmitoyl side chains of Pam3CysSerLys4 lipopeptide account for its powerful adjuvanticity to HLA class I-restricted CD8+ T lymphocytes. Eur J Immunol, 2003, 33(7), 204.
92. Hertz, CJ; Kiertscher, SM; Godowski, PJ; Bouis, DA; Norgard, MV; Roth, MD; Modlin, RL. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol, 2001, 166(4), 2444-50.
93. Michelsen, KS; Aicher, A; Mohaupt, M; Hartung, T; Dimmeler, S; Kirschning, CJ; Schumann, RR. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J Biol Chem, 2001, 276(28), 25680-6.
94. Kenny, EF; Talbot, S; Gong, M; Golenbock, DT; Bryant, CE; O’Neill, LA. MyD88 adaptor-like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol, 2009, 183(6), 3642-51.
95. Lombardi, V; Van Overtvelt, L; Horiot, S; et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy, 2008, 38(11), 1819-29.
96. Asai, Y; Makimura, Y; Ogawa, T. Toll-like receptor 2-mediated dendritic cell activation by a Porphyromonas gingivalis synthetic lipopeptide. J Med Microbiol, 2007, 56(Pt 4), 459-65.
97. Dearman, RJ; Cumberbatch, M; Maxwell, G; Basketter, DA; Kimber, I. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology, 2009, 126(4), 475-84.
98. Batzloff, MR; Pandey, M; Olive, C; Good, MF. Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res, 2006, 35(3), 233-48.
99. Link, C; Gavioli, R; Ebensen, T; Canella, A; Reinhard, E; Guzman, CA. The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur J Immunol, 2004, 34(3), 899-907.
100. Rharbaoui, F; Westendorf, A; Link, C; Felk, S; Buer, J; Gunzer, M; Guzman, CA. The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect Immun, 2004, 72(12), 6978-86.
101. Rharbaoui, F; Drabner, B; Borsutzky, S; Winckler, U; Morr, M; Ensoli, B; Muhlradt, PF; Guzman, CA. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol, 2002, 32(10), 2857-65.
102. Weigt, H; Muhlradt, PF; Emmendorffer, A; Krug, N; Braun, A. Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology, 2003, 207(3), 223-33.
103. Chua, BY; Healy, A; Cameron, PU; et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol, 2003, 81(1), 67-72.
104. Chua, BY; Zeng, W; Lau, YF; Jackson, DC. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine, 2007, 25(1), 92-101.
105. Jackson, DC; Lau, YF; Le, T; et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci, U S A, 2004, 101(43), 15440-5.
106. Eriksson, EM; Jackson, DC. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci, 2007, 8(4), 412-7.
107. BenMohamed, L; Krishnan, R; Auge, C; Primus, JF; Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology, 2002, 106(1), 113-21.
108. BenMohamed, L; Belkaid, Y; Loing, E; Brahimi, K; Gras-Masse, H; Druilhe, P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol, 2002, 32(8), 2274-81.
109. Robinson, JH; Case, MC; Brooks, CG. Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells. Immunology, 1992, 76(4), 593-8.
110. Moyle, PM; Toth, I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem, 2008, 15(5), 506-16.
111. BenMohamed, L; Wechsler, SL; Nesburn, AB. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis, 2002, 2(7), 425-31.
112. Schjetne, KW; Thompson, KM; Nilsen, N; Flo, TH; Fleckenstein, B; Iversen, JG; Espevik, T; Bogen, B. Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol, 2003, 171(1), 32-6.
113. Zhu, X; Ramos, TV; Gras-Masse, H; Kaplan, BE; BenMohamed, L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol, 2004, 34(11), 3102-14.
114. Moyle, PM; Olive, C; Good, MF; Toth, I. Method for the synthesis of highly pure vaccines using the lipid core peptide system. J Pept Sci, 2006, 12(12), 800-7.
115. Hayman, WA; Toth, I; Flinn, N; Scanlon, M; Good, MF. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol, 2002, 80(2), 178-87.
116. Horvath, A; Olive, C; Wong, A; Clair, T; Yarwood, P; Good, M; Toth, I. Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes. J Med Chem, 2002, 45(6), 1387-90.
117. Toth, I. A novel chemical approach to drug delivery: lipidic amino acid conjugates. J Drug Target, 1994, 2(3), 217-39.
118. Simerska, P; Abdel-Aal, AB; Fujita, Y; et al. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. J Med Chem, 2008, 51(5), 1447-52.
119. Abdel-Aal, AB; Batzloff, MR; Fujita, Y; et al. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem, 2008, 51(1), 167-72.
120. Zaman, M; Abdel-Aal, AB; Phillipps, KS; Fujita, Y; Good, MF; Toth, I. Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine 2009.
121. Pignatello, R; Puleo, A; Guccione, S; Raciti, G; Acquaviva, R; Campisi, A; Ventura, CA; Puglisi, G. Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids. I. Synthesis and biological evaluation of lipophilic conjugates of tranylcypromine. Eur J Med Chem, 2005, 40(11), 1074-9.
122. Pignatello, R; Guccione, S; Castelli, F; Sarpietro, MG; Giurato, L; Lombardo, M; Puglisi, G; Toth, I. Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids II. Experimental and computational evidence using biomembrane models. Int J Pharm, 2006, 310(1-2), 53-63.
123. Tavelin, S; Hashimoto, K; Malkinson, J; Lazorova, L; Toth, I; Artursson, P. A new principle for tight junction modulation based on occludin peptides. Mol Pharmacol, 2003, 64(6), 1530-40.
124. Wessling, ST; Ross, BP; Koda, Y; Blanchfield, JT; Toth, I. Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. Bioorg Med Chem, 2007, 15(14), 4946-50.
125. Drouillat, B; Hillery, AM; Dekany, G; Falconer, R; Wright, K; Toth, I. Novel liposaccharide conjugates for drug and peptide delivery. J Pharm Sci, 1998, 87(1), 25-30.
126. Phillipps, KS; Wykes, MN; Liu, XQ; Brown, M; Blanchfield, J; Toth, I. A novel synthetic adjuvant enhances dendritic cell function. Immunology, 2009, 128(1 Suppl), e582-8.
127. Yong, M; Mitchell, D; Caudron, A; Toth, I; Olive, C. Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines., Vaccine, 2009, 27(25-26), 3313-8.